Neisserial vaccine compositions comprising a combination of antigens

Abstract

The present invention relates to immunogenic compositions and vaccines for the treatment and prevention of Neisserial disease. Immunogenic compositions of the invention contain combinations of antigens selected from at least two different classes of antigens including adhesins, autotransporter proteins, toxins, iron acquisitions proteins and membrane-associated protein (preferably integral outer membrane protein)s. Such combinations of antigens are able to target the immune response against different aspects of the neisserial life cycle, resulting in a more effective immune response.

1 . An immunogenic composition comprising two or more different antigens, wherein the antigens are selected from at least two of the following categories:
 a) at least one Neisserial adhesin;   b) at least one Neisserial autotransporter;   c) at least one Neisserial toxin;   d) at least one Neisserial Fe acquisition protein; or   e) at least one Neisserial membrane associated protein, preferably integral outer membrane protein.   
     
     
         2 . The immunogenic composition of  claim 1  comprising an outer membrane vesicle preparation, wherein the antigens have been upregulated in the outer membrane vesicle. 
     
     
         3 . A genetically engineered Neisserial strain from which the outer membrane vesicle preparation of  claim 2  is derived. 
     
     
         4 . A vaccine comprising the immunogenic composition of  claim 1  and a pharmaceutically acceptable carrier. 
     
     
         5 . A method for treatment or prevention of Neisserial disease comprising administering a protective dose of the vaccine of  claim 4  to a host in need thereof. 
     
     
         6 . A method of preparing an immune globulin for use in prevention or treatment of Neisserial infection comprising the steps of immunizing a recipient with the vaccine of  claim 4  and isolating immune globulin from the recipient. 
     
     
         7 . A vaccine comprising one or more polynucleotide(s) encoding two or more different proteins whose expression is driven by a eukaryotic promoter, wherein the proteins are selected from at least two of the following categories:
 a) at least one Neisserial adhesin selected from the group consisting of FhaB, NspA, PilC, Hsf, Hap, MafA, MafB, Omp26, NMB0315, NMB0995, NMB1 119 and NadA;   b) at least one Neisserial autotransporter selected from the group consisting of Hsf, Hap, IgA protease, AspA and NadA;   c) at least one Neisserial toxin selected from the group consisting of FφA, FφC, FφA/C, VapD and NM-ADPRT;   d) at least one Neisserial Fe acquisition protein selected from the group consisting of TbpA high, TbpA low, TbpB high, TbpB low, LbpA, LbpB, P2086, HpuA, HpuB, Lipo28, Sibp, FbpA, BfrA, BfrB, Bcp, NMB0964 and NMB0293; or   e) at least one Neisserial membrane associated protein, preferably integral outer membrane protein selected from the group consisting of PilQ, OMP85, FhaC, NspA, TbpAfhigh), TbpA(low), LbpA, HpuB, TspA, TspB, TdfH, PorB, HimD, HisD, GNA1870, OstA, HlpA, MltA, NMB 1124, NMB 1162, NMB 1220, NMB 1313, NMB 1953, HtrA and PldA.   
     
     
         8 . A method for treatment or prevention of Neisserial disease comprising administering a protective dose of the vaccine of  claim 7  to a host in need thereof.